Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Artivion, Inc. Common Stock (NY:AORT)

45.38 -2.12 (-4.45%)
Streaming Delayed Price Updated: 1:57 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Artivion, Inc. Common Stock

< Previous 1 2 3 4 Next >
3 Profitable Stocks with Warning Signs
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned... 
Via StockStory
Topics ETFs Stocks World Trade
3 Small-Cap Stocks Skating on Thin Ice
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Earnings Scheduled For May 5, 2025
 
Via Benzinga
Breaking Down Artivion: 4 Analysts Share Their Views
 
Via Benzinga
Where Artivion Stands With Analysts
 
Via Benzinga
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Q1 Earnings Highs And Lows: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including... 
Via StockStory
AORT Q1 Earnings Call: Early Product Launches and Supply Recovery Drive Outperformance
Medical device company Artivion (NYSE:AORT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 1.6% year on year to $98.98 million. The company’s full-year revenue... 
Via StockStory
Topics Economy
3 High-Flying Stocks with Questionable Fundamentals
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
1 Healthcare Stock with Exciting Potential and 2 to Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
What Analysts Are Saying About Artivion Stock
 
Via Benzinga
Artivion’s (NYSE:AORT) Q1: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations
Medical device company Artivion (NYSE:AORT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 1.6% year on year to $98.98 million. The company’s full-year revenue... 
Via StockStory
Artivion (AORT) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company Artivion (NYSE:AORT) will be reporting earnings tomorrow after the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
3 Stocks Under $50 That Concern Us
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
1 Profitable Stock to Target This Week and 2 to Steer Clear Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Topics Artificial Intelligence
Reflecting On Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks’ Q4 Earnings: Merit Medical Systems (NASDAQ:MMSI)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Merit Medical Systems... 
Via StockStory
Unpacking Q4 Earnings: Artivion (NYSE:AORT) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Artivion (NYSE:AORT) and... 
Via StockStory
1 Small-Cap Stock on Our Watchlist and 2 to Avoid
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Artivion (AORT): Buy, Sell, or Hold Post Q4 Earnings?
Over the last six months, Artivion shares have sunk to $24.36, producing a disappointing 8.5% loss - worse than the S&P 500’s 1.4% drop. This was partly due to its softer quarterly results and might... 
Via StockStory
Topics Stocks Supply Chain
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q4 Earnings: ICU Medical (NASDAQ:ICUI) Best of the Bunch
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including ICU Medical (NASDAQ:ICUI) and its peers. 
Via StockStory
ICU Medical (ICUI) Q4 Earnings Report Preview: What To Look For
Medical device company ICU Medical (NASDAQ:ICUI) will be reporting results tomorrow after market close. Here’s what you need to know. 
Via StockStory
Artivion (AORT) Stock Trades Down, Here Is Why
Shares of medical device company Artivion (NYSE:AORT) fell 11.2% in the morning session after the company reported weak fourth-quarter 2024 results, as both revenue and EPS missed Wall Street's... 
Via StockStory
Artivion (NYSE:AORT) Misses Q4 Sales Targets
Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 3.9% year on year to $97.31 million. The company’s full-year revenue guidance of $427.5... 
Via StockStory
Artivion (AORT) Q4 Earnings: What To Expect
Medical device company Artivion (NYSE:AORT) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
Earnings Scheduled For February 24, 2025
 
Via Benzinga
Artivion (NYSE:AORT) Q3 Earnings: Leading The Medical Devices & Supplies - Cardiology, Neurology, Vascular Pack
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Artivion (NYSE:AORT) and its peers. 
Via StockStory
Unpacking Q3 Earnings: ICU Medical (NASDAQ:ICUI) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including... 
Via StockStory
Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q3
Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSE:PEN) and its peers. 
Via StockStory
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Merit Medical Systems (NASDAQ:MMSI) Vs The Rest
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Merit Medical Systems... 
Via StockStory
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.